Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients With Acute Decompensated Alcoholic Hepatitis.

NCT03452540 is registered in ClinicalTrials.gov with Afimmune as lead sponsor.

NCT NCT03452540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03452540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients With Acute Decompensated Alcoholic Hepatitis.
Lead sponsor
Afimmune
Phase
Phase 2
Overall status
Terminated
Start date
November 28, 2018
Completion date
March 31, 2020
Enrollment
9 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

severe acute decompensated alcoholic hepatitis